Literature DB >> 29037791

Effect of optogenetic modulation on entopeduncular input affects thalamic discharge and behavior in an AAV2-α-synuclein-induced hemiparkinson rat model.

Hyeong Cheol Moon1, So Yoon Won2, Eung Gook Kim2, Hyong Kyu Kim3, Chul Bum Cho4, Young Seok Park5.   

Abstract

OBJECTIVE: Neuromodulation of the globus pallidus internus(GPi) alleviates Parkinson's disease symptoms. The primate GPi is homologous to the rat entopeduncular nucleus (EP). The aim of the present study was to determine if optogenetic modulation of the EP could alter parkinsonian behavior or thalamic discharge in a hemiparkinson rat model.
METHODS: We injected an adeno-associated virus type-2 expressing α-synuclein (AAV2-α-syn) into the substantia nigra pars compacta (SNc) of the right hemisphere and confirmed parkinsonian behavior using an amphetamine-induced rotation test. Then we injected activated or inhibited neurons, using the channelrhodopsin2 (ChR2)/halorhodopsin (NpHR) system in the EP of the hemiparkinson rat model and examined downstream effects in vivo. We assessed alterations in parkinsonian behaviors using the stepping and cylinder tests before, during, and after optogenetic stimulation.
RESULTS: Importantly, optogenetic inhibition of the EP improved parkinsonian motor behaviors. When we monitored thalamic neuronal activity following optogenetic neuromodulation in vivo, and we observed alterations in thalamic discharge The thalamic neuronal activity is increased for optogenetic inhibition stimulation, whereas decreased for optogenetic activation stimulation.
CONCLUSIONS: Taken together, our data demonstrate that optical neuromodulation of the EP can successfully control contralateral forelimb movement and thalamic discharge in an AAV2-α-synuclein-induced hemiparkinson rat model.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Hemiparkinson rat model; Neural cell recording; Optogenetics; entoPeduncular

Mesh:

Substances:

Year:  2017        PMID: 29037791     DOI: 10.1016/j.neulet.2017.10.019

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

Review 1.  New era of optogenetics: from the central to peripheral nervous system.

Authors:  Xiang Xu; Thomas Mee; Xiaofeng Jia
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-02-18       Impact factor: 8.250

2.  Model-based optogenetic stimulation to regulate beta oscillations in Parkinsonian neural networks.

Authors:  Ying Yu; Fang Han; Qishao Wang; Qingyun Wang
Journal:  Cogn Neurodyn       Date:  2021-10-16       Impact factor: 3.473

3.  Change of Extracellular Glutamate Level in Striatum during Deep Brain Stimulation of the Entopeduncular Nucleus in Rats.

Authors:  Hyun-Ju Lee; Jae Hoon Sung; Jae Taek Hong; Il Sup Kim; Seung Ho Yang; Chul Bum Cho
Journal:  J Korean Neurosurg Soc       Date:  2019-02-27

4.  Attenuation of Hippocampal Evoked Potentials in vivo by Activation of GtACR2, an Optogenetic Chloride Channel.

Authors:  Anirudh R Acharya; Lars Emil Larsen; Wouter Van Lysebettens; Wytse Jan Wadman; Jean Delbeke; Kristl Vonck; Alfred Meurs; Paul Boon; Robrecht Raedt
Journal:  Front Neurosci       Date:  2021-03-29       Impact factor: 4.677

Review 5.  Adeno-Associated Viral Vectors as Versatile Tools for Parkinson's Research, Both for Disease Modeling Purposes and for Therapeutic Uses.

Authors:  Ana Fajardo-Serrano; Alberto J Rico; Elvira Roda; Adriana Honrubia; Sandra Arrieta; Goiaz Ariznabarreta; Julia Chocarro; Elena Lorenzo-Ramos; Alvaro Pejenaute; Alfonso Vázquez; José Luis Lanciego
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

Review 6.  Gene Therapy for Parkinson's Disease, An Update.

Authors:  Tobias M Axelsen; David P D Woldbye
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

Review 7.  Thalamic afferents to prefrontal cortices from ventral motor nuclei in decision-making.

Authors:  Bianca Sieveritz; Marianela García-Muñoz; Gordon W Arbuthnott
Journal:  Eur J Neurosci       Date:  2018-12-03       Impact factor: 3.386

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.